Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
GDC-0349
Cat. No.:
OB0225LY-0444
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, CSFC and LC-MS.
Size:
Product Overview
Description:
GDC-0349 is a small molecule targeted drug mainly used to study tumor models associated with PTEN deletion.
Synonym:
RG-7603; 1207360-89-1; (S)-1-Ethyl-3-(4-(4-(3-methylmorpholino)-7-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea; 1-Ethyl-3-[4-[4-[(3S)-3-methylmorpholin-4-yl]-7-(oxetan-3-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]phenyl]urea
CAS No.:
1207360-89-1
Compound CID:
59239165
Formula:
C24H32N6O3
Formula Weight:
452.55
Specification
Relative Density:
1.269 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
GDC-0349 can be used to study tumor biology.
Library Information
Targets:
PI3K family; PIKKs
Receptors:
mTOR; PI3Kα
Pathways:
PI3K/Akt/mTOR signaling; Autophagy
Plate Number:
AOCL-6
Plate Location:
f11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
84 mg/mL; 185.6 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
6 mg/mL; 13.25 mM
ALogP:
1.982
HBA_Count:
5
HBD_Count:
2
Rotatable Bond:
5
